HFpEF Management 2026: SGLT2 Inhibitors and Spironolactone Show Mixed Results

Executive Brief

News Report

The News: ACC 2026 conference updates HFpEF treatment landscape.
Clinical Win: SGLT2 inhibitors show promise while spironolactone shows no benefit.
Target Specialty: cardiology

Key Data at a Glance

SPIRIT-HF trial enrollment: 730 patients
Heart failure hospitalization event rates: 10.8% placebo vs 12.7% spironolactone

The recent ACC 2026 conference highlighted the evolving treatment landscape for heart failure with preserved ejection fraction (HFpEF), particularly the roles of SGLT2 inhibitors and spironolactone. Notably, the SPIRIT-HF trial presented findings that challenge the efficacy of spironolactone in this patient population, while SGLT2 inhibitors continue to show promise in reducing hospitalizations.

Clinical Context

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by symptoms of heart failure despite a normal ejection fraction. It is increasingly recognized as a significant public health challenge, affecting millions of patients worldwide. The condition is often associated with comorbidities such as hypertension, obesity, and diabetes, leading to a high burden of morbidity and mortality. Current treatment strategies primarily focus on symptom management and the reduction of hospitalizations. SGLT2 inhibitors, originally developed for diabetes management, have emerged as a promising option for HFpEF, demonstrating positive effects on cardiovascular outcomes. However, the role of spironolactone, an established diuretic and aldosterone antagonist, remains uncertain, particularly in light of recent trial results.

Key Findings

The SPIRIT-HF trial showed spironolactone did not significantly reduce heart failure hospitalizations or cardiovascular death compared to placebo in patients with HFpEF (10.8 vs 12.7 events per 100 patient-years) [10].

The trial enrolled 730 symptomatic patients with HFpEF or mildly reduced ejection fraction across 56 centers in four European countries [10].

The primary endpoint was a composite of heart failure hospitalization and death from cardiovascular causes [10].

Safety & Tolerability

Event rates: 10.8% in the placebo group versus 12.7% in the spironolactone group for the composite endpoint of heart failure hospitalization and cardiovascular death [10].

What This Means for Clinical Practice

The findings from the SPIRIT-HF trial raise important considerations for clinicians treating patients with HFpEF. While SGLT2 inhibitors continue to demonstrate efficacy in reducing hospitalizations, the lack of benefit from spironolactone suggests that clinicians should be cautious in prescribing this medication for HFpEF patients. The trial highlights the necessity of individualized treatment approaches that consider patient comorbidities and potential adverse effects. As the landscape of HFpEF management evolves, ongoing research and clinical trials will be essential in refining treatment strategies and improving patient outcomes. Clinicians should remain vigilant regarding the safety profiles of these medications, particularly in light of the increased hospitalization rates associated with spironolactone use. Furthermore, the integration of new therapeutic options, such as adjunctive therapies, may provide additional benefits in managing this challenging condition.

Clinical Perspective

Workflow: Clinicians should reassess the use of spironolactone in HFpEF management based on recent trial findings.

Economics: The lack of efficacy in spironolactone may impact healthcare costs associated with heart failure hospitalizations.

Patient Outcomes: Ongoing research is needed to identify effective treatment strategies that improve outcomes for patients with HFpEF.

Dr. Kavya Sharma, Cardiology

References

ACC — SPIRIT-HF: Does Spironolactone Benefit Patients With HFpEF?

HFpEF Management 2026: SGLT2 Inhibitors and Spironolactone Show Mixed Results

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for HFpEF: 20% Reduction in Heart Failure Events

Baxdrostat Reduces Resistant Hypertension: Comparison with Spironolactone and Eplerenone

Baxdrostat Targets Aldosterone Pathway: New Algorithm for Resistant Hypertension Management

Verified HCP Portal